Holen Sie sich die Stockscreener-App
4.93
0.20%
0.010
An 2 Therapeutics Inc Aktie (ANTX) Neueste Nachrichten
MapLight Therapeutics stock tumbles 50% on mixed phase 2 schizophrenia data (MPLT:NASDAQ) - Seeking Alpha
4D Molecular Therapeutics (Nasdaq: FDMT) posts positive 2-year wet AMD data - Stock Titan
Intensity Therapeutics, Inc. Restarts Patient Treatment in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 Study) - PR Newswire
TG Therapeutics (TGTX) Starts Phase 2 Briumvi Trial - Yahoo Finance
Chemomab Therapeutics and Precision Medicine Pioneer Scipher Medicine Announce Merger Agreement to Advance Nebokitug in an AI-Powered Phase 2 Trial in Rheumatoid Arthritis - GlobeNewswire
GX-03 Phase 2 signals guide new Stage 2 plan at Turn Therapeutics (NASDAQ: TTRX) - Stock Titan
Axsome Therapeutics Initiates FOCUS-2 Phase 3 Trial of - GlobeNewswire
Turn Therapeutics to Host Webcast Presenting Comprehensive Interim Analysis and Optimized Stage 2 Design for GX-03 in Atopic Dermatitis - Business Wire
Form 4 Spyre Therapeutics Inc For: 2 July By Investing.com - Investing.com Nigeria
Form 4 Nuo Therapeutics Inc For: 2 July By Investing.com - Investing.com Canada
Form 4 Apogee Therapeutics Inc For: 2 July By Investing.com - Investing.com Nigeria
Form 4 Vyne Therapeutics Inc For: 2 July By Investing.com - Investing.com Nigeria
Form 4 Monopar Therapeutics Inc For: 2 July By Investing.com - Investing.com Nigeria
Form 4 Tango Therapeutics Inc For: 2 July By Investing.com - Investing.com Nigeria
Form 4 Lineage Cell Therapeutics Inc For: 2 July By Investing.com - Investing.com India
Form 4 Alaunos Therapeutics Inc For: 2 July By Investing.com - Investing.com UK
Form 4 VistaGen Therapeutics Inc For: 2 July By Investing.com - Investing.com Canada
Form 4 Oncotelic Therapeutics Inc For: 2 July By Investing.com - Investing.com India
Intellia Therapeutics, Inc. SEC Filing (Jul 2, 2026) - Stock Titan
Talawar Therapeutics and JATT II Acquisition Corp. Announce Definitive Business Combination Agreement to Create Publicly Listed Biotechnology Company Developing Potentially Best-in-Class Bispecifics for I&I Diseases - BioSpace
Gain Therapeutics (GANX) wins FDA IND clearance to start GT-02287 Phase 2 Parkinson’s trial - Stock Titan
Star Therapeutics to Present Complete Data from Phase 1/2 Multidose Study of VGA039 in Von Willebrand Disease at ISTH 2026 Congress - Business Wire
Kymera Therapeutics (KYMR) Extends Rally On Sanofi Milestone And Lupus Data - StocksToTrade
BioRestorative Therapies Announces Completion of BRTX-100 - GlobeNewswire
Protagonist Therapeutics, Inc. Stock 12‑Month Price Target Raised to $119.15, Implies 2% Downside - TradingView
Akebia Therapeutics And 2 Other Promising Penny Stocks To Watch - simplywall.st
DiaMedica Therapeutics Announces First Patients Dosed in Phase 2 Trial of DM199 for the Treatment of Fetal Growth Restriction - Business Wire
SYRE Stock Climbs As TL1A Data Ignite Analyst Upgrades - StocksToTrade
APGE Stock Climbs As Street Backs Zumilokibart Momentum - StocksToTrade
Allarity Therapeutics to Present Trial-in-Progress Poster - GlobeNewswire
Edgewise Therapeutics Announces Positive Top-Line Data from 12-Week Phase 2 CIRRUS-HCM Trial with EDG-7500 in Obstructive and Nonobstructive Hypertrophic Cardiomyopathy (HCM) - PR Newswire
Elicio Therapeutics Reports Results from Phase 2 AMPLIFY-7P - GlobeNewswire
Lexeo Therapeutics Announces Regulatory Update and - GlobeNewswire
Enliven Therapeutics Stock Surges On ELVN-001 Breakthrough And $400M Raise - StocksToTrade
Rein Therapeutics Expands Phase 2 RENEW Trial into United Kingdom - GlobeNewswire
IPF trial for LTI-03 adds first UK patient, expands to 3 countries - Stock Titan
TGTX Stock Surges As Briumvi Pipeline Momentum Accelerates - StocksToTrade
Tectonic Therapeutic Completes Enrollment in TX45 APEX Phase 2 Clinical Trial in PH-HFpEF Patients - GlobeNewswire
TG Therapeutics Announces Positive Topline Phase 1 Data for - GlobeNewswire
Tango Therapeutics Announces Combination of Vopimetostat - GlobeNewswire
Structure Therapeutics (GPCR) Reports Positive Phase 2 Weight Loss Data for Aleniglipron - Yahoo Finance
AN2 Therapeutics Reports Positive Enabling Data Supporting Advancement of Oral AN2-502998 to Phase 2 Study for Chronic Chagas Disease - Business Wire
Vertex Pharmaceuticals Inc Stock (VRTX) Closed Down by 3.03% on Jun 2: Facts Behind the Movement - TradingKey
Convergent Therapeutics Announces Positive Phase 2 Data at ASCO 2026 Showing Promising Anti-Tumor Activity, Durability, and Favorable Tolerability for CONV01-α in Lu-PSMA-Exposed Metastatic Castration-Resistant Prostate Cancer (mCRPC) - Business Wire
Turn Therapeutics Reports Interim Analysis Findings and Adaptive Optimization Strategy from Phase 2 GX-03 Trial in Moderate-to-Severe Atopic Dermatitis - Business Wire
Avenzo Therapeutics Presents Updated Results from the Phase 1/2 Study of AVZO-021, a Potentially Differentiated CDK2 Inhibitor, at the 2026 American Society of Clinical Oncology Annual Meeting - Business Wire
Monopar Therapeutics Presents Phase 2 Data for ALXN1840 at EASL Congress 2026, Demonstrating Liver Disease Stabilization and Neurological Improvements in Wilson Disease Patients - Quiver Quantitative
Skyhawk Therapeutics Announces Twelve-Month Interim Results from Phase 1/2 Clinical Trial of SKY-0515 in Huntington's Disease - PR Newswire
Apogee Therapeutics, Inc. (APGE) Discusses Positive Part B Results From Phase 2 APEX Trial of Zumilokibart in Atopic DermatitisSlideshow (NASDAQ:APGE) 2026-05-30 - Seeking Alpha
Monopar Therapeutics (MNPR) shares Phase 2 Wilson disease data at EASL 2026 - Stock Titan
C4 Therapeutics, Inc. unveils Phase 2 trial progress for cemsidomide at ASCO26 - Traders Union
Atossa Therapeutics Announces ASCO 2026 Abstracts Highlighting (Z)-Endoxifen Activity Across ESR1 Mutations and Ongoing EVANGELINE Phase 2 Trial - PR Newswire
Crystalys Therapeutics Doses First Patients in New Phase 2 Trial of Dotinurad for Difficult-to-Treat Gout - PR Newswire
This Summit Therapeutics Analyst Is No Longer Bullish; Here Are Top 2 Downgrades For Friday - Benzinga
Obsidian Therapeutics to Present Phase 2 Clinical Data for OBX-115 in Advanced Melanoma in Oral Presentation at 2026 ASCO Annual Meeting - BioSpace
Convergent Therapeutics to Present Largest Set of Prospective Phase 2 Data for an Alpha Radiopharmaceutical in Lu-PSMA-Exposed Metastatic Castration-Resistant Prostate Cancer at ASCO 2026 - Business Wire
DiaMedica Therapeutics Announces 75% Enrollment Milestone in ReMEDy2 Phase 2/3 Acute Ischemic Stroke Trial - Business Wire
Relay Therapeutics (Nasdaq: RLAY) shares early zovegalisib vascular anomaly data - Stock Titan
Amplexd Therapeutics Initiates Phase 2 Clinical Trial of Investigational EGCg-Based HPV Therapy - GlobeNewswire
Quince Therapeutics Announces Clinically Meaningful Improvements Across Functional, Hemodynamic and Biomarker Measures in Phase 2 Study in PAH and PH-ILD - GlobeNewswire
Tenaya Therapeutics, Inc. (TNYA) Discusses RIDGE-1 Phase Ib/II Data on TN-401 Gene Therapy for PKP2-Associated ARVCSlideshow (NASDAQ:TNYA) 2026-05-17 - Seeking Alpha
1.97%
0.83%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):